Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the HepASA Trial

H. Carp

DOI: https://doi.org/10.3899/jrheum.090310

2010-01-01

Abstract:To the Editor: Laskin, et al 1 claim that low molecular weight heparin and aspirin (LMWH/ASA) did not confer incremental benefit compared to ASA alone in women with recurrent pregnancy loss and either autoantibodies or a coagulation abnormality. However, the inclusion criteria were so wide as to preclude any significant results. Patients with 2 unexplained consecutive pregnancy losses prior to 32 weeks’ gestation have an 80% chance of a subsequent live birth. No treatment will significantly increase the live birth rate over 80%. Blighted ova resulting in first-trimester abortions and pregnancy losses at 32 weeks starting with …